- PolyPid develops a platform technology to provide locally controlled and continuous delivery of medications.
- Lead product candidate D-PLEX100 is investigated for the prevention of sternal and abdominal surgical site infections serving a huge market.
- Meaningful interim results and topline data from pivotal Phase 3 SHIELD I clinical trial will soon be published.
- Measured in terms of the clinical benefit of D?PLEX100 and its estimated market size, PolyPid is clearly undervalued at present in our view.
For further details see:
PolyPid: Strong Pipeline, Close Catalysts